Amgen Revenue and Competitors
Estimated Revenue & Valuation
- Amgen's estimated annual revenue is currently $25.8B per year.
- Amgen's estimated revenue per employee is $639,772
- Amgen's total funding is $68M.
- Amgen's current valuation is $132.6B. (January 2022)
Employee Data
- Amgen has 40280 Employees.
- Amgen grew their employee count by 10% last year.
Amgen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Microsoft Viva Service Owner and Technical Lead | Reveal Email/Phone |
2 | Production Process Owner | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | Executive Director & Head Technology, Business Development | Reveal Email/Phone |
5 | Chief Staff, Operations Product Advancement | Reveal Email/Phone |
6 | Executive Director Regional Sales | Reveal Email/Phone |
7 | Associate VP, Drug Product Process Development | Reveal Email/Phone |
8 | Scientific VP | Reveal Email/Phone |
9 | Associate VP, Head Digital Health & Innovation | Reveal Email/Phone |
10 | Scientific VP | Reveal Email/Phone |
Amgen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $16.1M | 80 | 1% | N/A | N/A |
#2 | $69340M | 107310 | 4% | N/A | $308.4B |
#3 | $3847.1M | 24820 | -1% | N/A | N/A |
#4 | $55170M | 56697 | 5% | $10.9M | $240.2B |
#5 | $11100M | 10056 | -10% | £6M | N/A |
What Is Amgen?
Amgen, Inc. is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The Company manufactures and markets four human therapeutic products, EPOGEN (Epoetin alfa), NEUPOGEN (Filgrastim), INFERGEN (Interferon alfacon-1) and STEMGEN (Ancestim). Amgen uses wholesale distributors of pharmaceutical products as the principal means of distributing the Company's products to clinics, hospitals and pharmacies.
keywords:Biotechnology
$68M
Total Funding
40280
Number of Employees
$25.8B
Revenue (est)
10%
Employee Growth %
$132.6B
Valuation
N/A
Accelerator
Amgen News
On the other hand, Sanofi and Regeneron argue that upholding of Amgen's patents could allow companies to swat down entire classes of drugs by offering overly...
CHANGING HANDSAmgen's former Building No. 34 has been sold to the Latigo Group, the same firm developing 299 E. Thousand Oaks Blvd. Last...
In Amgen v. Sanofi, the Supreme Court has been asked to review Federal Circuit precedent on the enablement doctrine found in 35 U.S.C....
Beginning October 21, Amgen's R&D podcast returns with the new series, Undruggable. Produced in partnership with The Scientist, Undruggable explores the latest wave of innovation, featuring conversations about the new types of multispecific medicines that have the potential to radically alter ou ...
It's safe to say that family dinners at the Reese household were never boring. Dr. David Reese, executive vice president of Research and Development at Amgen, and his brother Dr. Jim Reese, former Chief Operations Engineer and employee #18 at Google and current advisory board member for Harvard ...